Literature DB >> 10448133

The biology of Epstein-Barr virus: lessons learned from the virus and the host.

J I Cohen1.   

Abstract

Recent studies indicate that a large proportion of cytotoxic T cells are directed towards the Epstein-Barr virus (EBV) during both acute infection and convalescence. The virus, in turn, has usurped cellular pathways to promote proliferation of infected cells and has pirated cellular genes into its genome to modulate the immune system to allow lifelong infection of humans. Analysis of the immune response to the virus is leading to novel therapies for EBV-associated malignancies, including the use of virus-specific cytotoxic T cell infusions.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10448133     DOI： 10.1016/S0952-7915(99)80062-4

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  12 in total

1.  Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Raquel Gomez; Bianca Heemskerk; Mireille Toebes; Maureen M Mullen; Theodore S Jardetzky; Richard Longnecker; Marco W Schilham; Tom H M Ottenhoff; Jacques Neefjes; Ton N Schumacher; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

Review 2.  Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.

Authors:  Shannon Kenney
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

3.  Activation of human herpesvirus replication by apoptosis.

Authors:  Alka Prasad; Jill Remick; Steven L Zeichner
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

4.  Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis.

Authors:  Vincent F Biank; Mehul K Sheth; Julie Talano; David Margolis; Pippa Simpson; Subra Kugathasan; Michael Stephens
Journal:  J Pediatr       Date:  2011-06-30       Impact factor: 4.406

5.  The Potential for EBV Vaccines to Prevent Multiple Sclerosis.

Authors:  Peter A Maple; Alberto Ascherio; Jeffrey I Cohen; Gary Cutter; Gavin Giovannoni; Claire Shannon-Lowe; Radu Tanasescu; Bruno Gran
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

6.  Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma.

Authors:  Susanna H Hutajulu; Eveline K Hoebe; Sandra Awm Verkuijlen; Jajah Fachiroh; Bambang Hariwijanto; Sofia M Haryana; Servi Jc Stevens; Astrid E Greijer; Jaap M Middeldorp
Journal:  Infect Agent Cancer       Date:  2010-09-19       Impact factor: 2.965

7.  Expansion of a CD28-intermediate subset among CD8 T cells in patients with infectious mononucleosis.

Authors:  Hiroshi Uda; Toru Mima; Norihiko Yamaguchi; Yoshinori Katada; Masayuki Fukuda; Naohiko Fujii; Kojiro Nakamura; Osamu Saiki
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Exacerbated metastatic disease in a mouse mammary tumor model following latent gammaherpesvirus infection.

Authors:  Vinita S Chauhan; Daniel A Nelson; Lopamudra Das Roy; Pinku Mukherjee; Kenneth L Bost
Journal:  Infect Agent Cancer       Date:  2012-05-29       Impact factor: 2.965

9.  A Role for RNA Viruses in the Pathogenesis of Burkitt's Lymphoma: The Need for Reappraisal.

Authors:  Corry van den Bosch
Journal:  Adv Hematol       Date:  2011-11-29

10.  Deficient EBV-specific B- and T-cell response in patients with chronic fatigue syndrome.

Authors:  Madlen Loebel; Kristin Strohschein; Carolin Giannini; Uwe Koelsch; Sandra Bauer; Cornelia Doebis; Sybill Thomas; Nadine Unterwalder; Volker von Baehr; Petra Reinke; Michael Knops; Leif G Hanitsch; Christian Meisel; Hans-Dieter Volk; Carmen Scheibenbogen
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.